These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 38491265)

  • 1. Antithrombotic strategies for preventing graft failure in coronary artery bypass graft.
    Mauro MS; Finocchiaro S; Calderone D; Rochira C; Agnello F; Scalia L; Capodanno D
    J Thromb Thrombolysis; 2024 Apr; 57(4):547-557. PubMed ID: 38491265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.
    Harris J; Pouwels KB; Johnson T; Sterne J; Pithara C; Mahadevan K; Reeves B; Benedetto U; Loke Y; Lasserson D; Doble B; Hopewell-Kelly N; Redwood S; Wordsworth S; Mumford A; Rogers C; Pufulete M
    Health Technol Assess; 2023 May; 27(8):1-257. PubMed ID: 37435838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent.
    Zimmermann N; Gams E; Hohlfeld T
    Eur J Cardiothorac Surg; 2008 Jul; 34(1):93-108. PubMed ID: 18448350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic treatment after coronary artery bypass graft surgery: systematic review and network meta-analysis.
    Solo K; Lavi S; Kabali C; Levine GN; Kulik A; John-Baptiste AA; Fremes SE; Martin J; Eikelboom JW; Ruel M; Huitema AA; Choudhury T; Bhatt DL; Tzemos N; Mamas MA; Bagur R
    BMJ; 2019 Oct; 367():l5476. PubMed ID: 31601578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different antithrombotic strategies after coronary artery bypass grafting to prevent adverse events: a retrospective analysis.
    Shi Y; Chen S; Liu G; Lian B; Chen Y; Zhang L
    J Cardiothorac Surg; 2024 Jul; 19(1):422. PubMed ID: 38965617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of lipoproteins and antiplatelet agents on vein graft patency 1 year after coronary artery bypass grafting.
    Zhu J; Zhu Y; Zhang M; Xue Q; Hu J; Liu H; Wang R; Wang X; Zhao Q
    J Thorac Cardiovasc Surg; 2022 Mar; 163(3):1030-1039.e4. PubMed ID: 32359899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of clopidogrel versus aspirin as a maintenance monotherapy 1 year after coronary artery bypass grafting.
    Kim JS; Kang Y; Sohn SH; Hwang HY
    Eur J Cardiothorac Surg; 2023 Apr; 63(4):. PubMed ID: 37039835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary prevention after coronary artery bypass grafting: Anticoagulation and antiplatelet therapy is only one factor.
    Sellke FW
    J Card Surg; 2021 Mar; 36(3):1100-1102. PubMed ID: 33506999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clopidogrel and aspirin versus clopidogrel alone on graft patency after coronary artery bypass grafting.
    Gao C; Ren C; Li D; Li L
    Ann Thorac Surg; 2009 Jul; 88(1):59-62. PubMed ID: 19559191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery.
    Bedenis R; Lethaby A; Maxwell H; Acosta S; Prins MH
    Cochrane Database Syst Rev; 2015 Feb; 2015(2):CD000535. PubMed ID: 25695213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of ticagrelor versus aspirin on graft patency after CABG: Rationale and design of the TARGET (ticagrelor antiplatelet therapy to reduce graft events and thrombosis) randomized controlled trial (NCT02053909).
    Kulik A; Abreu AM; Boronat V; Kouchoukos NT; Ruel M
    Contemp Clin Trials; 2018 May; 68():45-51. PubMed ID: 29551675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study.
    Sun JC; Teoh KH; Lamy A; Sheth T; Ellins ML; Jung H; Yusuf S; Anand S; Connolly S; Whitlock RP; Eikelboom JW
    Am Heart J; 2010 Dec; 160(6):1178-84. PubMed ID: 21146675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Stein PD; Schünemann HJ; Dalen JE; Gutterman D
    Chest; 2004 Sep; 126(3 Suppl):600S-608S. PubMed ID: 15383486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Meta-Analysis Comparing Aspirin Alone Versus Dual Antiplatelet Therapy for the Prevention of Venous Graft Failure Following Coronary Artery Bypass Surgery.
    Hesterberg K; Rawal A; Khan S; Rashid A; Jones D; Siddiqui T; Khader TA; Nayyar M; Shah R
    Cardiovasc Revasc Med; 2020 Jun; 21(6):792-796. PubMed ID: 31672535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society.
    Fitchett D; Eikelboom J; Fremes S; Mazer D; Singh S; Bittira B; Brister S; Graham J; Gupta M; Karkouti K; Lee A; Love M; McArthur R; Peterson M; Verma S; Yau T
    Can J Cardiol; 2009 Dec; 25(12):683-9. PubMed ID: 19960127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombelastographic haemostatic status and antiplatelet therapy after coronary artery bypass surgery (TEG-CABG trial): assessing and monitoring the antithrombotic effect of clopidogrel and aspirin versus aspirin alone in hypercoagulable patients: study protocol for a randomized controlled trial.
    Rafiq S; Johansson PI; Zacho M; Stissing T; Kofoed K; Lilleør NB; Steinbrüchel DA
    Trials; 2012 Apr; 13():48. PubMed ID: 22540524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials.
    Verma S; Goodman SG; Mehta SR; Latter DA; Ruel M; Gupta M; Yanagawa B; Al-Omran M; Gupta N; Teoh H; Friedrich JO
    BMC Surg; 2015 Oct; 15():112. PubMed ID: 26467661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis.
    Deo SV; Dunlay SM; Shah IK; Altarabsheh SE; Erwin PJ; Boilson BA; Park SJ; Joyce LD
    J Card Surg; 2013 Mar; 28(2):109-16. PubMed ID: 23488578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet agents and anticoagulants for hypertension.
    Shantsila E; Kozieł-Siołkowska M; Lip GY
    Cochrane Database Syst Rev; 2022 Jul; 7():CD003186. PubMed ID: 35900898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.